Literature DB >> 25855822

Formulations for children: problems and solutions.

Hannah K Batchelor, John F Marriott.   

Abstract

Paediatric formulation design is complex as there is a need to understand the developmental physiological changes that occur during childhood and their impact on the absorption of drugs. Paediatric dose adjustments are usually based on achieving pharmacokinetic or pharmacodynamic profiles equivalent to those achieved in adult populations. However, differences in the way in which children handle adult products or the use of bespoke paediatric formulations can result in unexpected pharmacokinetic drug profiles with altered clinical efficacy. Differences in drug formulations need to be understood by healthcare professionals involved in the prescribing, administration or dispensing of drugs to children such that appropriate advice is given to ensure that therapeutic outcomes are achieved. This issue is not confined to oral medicines but is applicable for all routes of administration encountered in paediatric therapy.
© 2014 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25855822      PMCID: PMC4345951          DOI: 10.1111/bcp.12268

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  96 in total

1.  Direct measurement of ear canal volume in a pediatric population: can we explain its individual variation in terms of age and body weight?

Authors:  Heil Noh; Dong-Hee Lee
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2012-02-25       Impact factor: 1.675

2.  Effects of the quantity of water and milk ingested concomitantly with AS-924, a novel ester-type cephem antibiotic, on its pharmacokinetics.

Authors:  F Matsumoto; I Sakurai; M Morita; T Takahashi; N Mori; T Sugihara; A Sakai; S Yamaji; Y Akaike; K Yano
Journal:  Int J Antimicrob Agents       Date:  2001-11       Impact factor: 5.283

3.  Ophthalmic drops causing coma in an infant.

Authors:  R J Berlin; U T Lee; J R Samples; L F Rich; D D Tang-Liu; K A Sing; R D Steiner
Journal:  J Pediatr       Date:  2001-03       Impact factor: 4.406

4.  Pharmacokinetics, pharmacodynamics, and comparative bioavailability of single, oral 2-mg doses of dexamethasone liquid and tablet formulations: a randomized, controlled, crossover study in healthy adult volunteers.

Authors:  Christian Queckenberg; Bertil Wachall; Valerie Erlinghagen; Paola Di Gion; Dorota Tomalik-Scharte; Mona Tawab; Kathleen Gerbeth; Uwe Fuhr
Journal:  Clin Ther       Date:  2011-11-01       Impact factor: 3.393

5.  Comparison of the pharmacokinetics, safety and tolerability of two concentrations of a new liquid recombinant human growth hormone formulation versus the freeze-dried formulation.

Authors:  Bernd Liedert; Ulf Forssmann; Peter Wolna; Michaela Golob; Andreas Kovar
Journal:  BMC Clin Pharmacol       Date:  2010-10-20

Review 6.  The economics of pediatric formulation development for off-patent drugs.

Authors:  Christopher-Paul Milne; Jon B Bruss
Journal:  Clin Ther       Date:  2008-11       Impact factor: 3.393

7.  A randomised comparison of oral desmopressin lyophilisate (MELT) and tablet formulations in children and adolescents with primary nocturnal enuresis.

Authors:  H Lottmann; F Froeling; S Alloussi; A S El-Radhi; S Rittig; A Riis; B-E Persson
Journal:  Int J Clin Pract       Date:  2007-07-26       Impact factor: 2.503

8.  Facemasks versus mouthpieces for aerosol treatment of asthmatic children.

Authors:  D Lowenthal; M Kattan
Journal:  Pediatr Pulmonol       Date:  1992-11

9.  Plasma timolol in glaucoma patients.

Authors:  M S Passo; E A Palmer; E M Van Buskirk
Journal:  Ophthalmology       Date:  1984-11       Impact factor: 12.079

10.  Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.

Authors:  P Kasirye; L Kendall; K K Adkison; C Tumusiime; M Ssenyonga; S Bakeera-Kitaka; P Nahirya-Ntege; T Mhute; A Kekitiinwa; W Snowden; D M Burger; D M Gibb; A S Walker
Journal:  Clin Pharmacol Ther       Date:  2011-12-21       Impact factor: 6.875

View more
  31 in total

1.  Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag.

Authors:  Margaux Boehler; Shirin Bruderer; Ivan Ulč; Jasper Dingemanse
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-02       Impact factor: 2.441

2.  Paediatric prescribing: why children are not small adults.

Authors:  Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

3.  Pediatric ocular nanomedicines: Challenges and opportunities.

Authors:  Natasha D Sheybani; Hu Yang
Journal:  Chin Chem Lett       Date:  2017-07-26       Impact factor: 6.779

Review 4.  Moving toward a paradigm shift in the regulatory requirements for pediatric medicines.

Authors:  William Wei Lim Chin; Angelika Joos
Journal:  Eur J Pediatr       Date:  2016-09-19       Impact factor: 3.183

5.  Taste Perceptions of Common Pediatric Antibiotic Suspensions and Associated Prescribing Patterns in Medical Residents.

Authors:  Neelkamal Soares; Rachel Mitchell; Theresa McGoff; Teresa Bailey; Gregory S Wellman
Journal:  J Pediatr Pharmacol Ther       Date:  2022-05-09

6.  Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity.

Authors:  Duhyeong Hwang; Taylor Dismuke; Andrey Tikunov; Elias P Rosen; John R Kagel; Jacob D Ramsey; Chaemin Lim; William Zamboni; Alexander V Kabanov; Timothy R Gershon; Marina Sokolsky-Papkov PhD
Journal:  Nanomedicine       Date:  2020-11-28       Impact factor: 5.307

Review 7.  Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms.

Authors:  Felipe L Lopez; Terry B Ernest; Catherine Tuleu; Mine Orlu Gul
Journal:  Expert Opin Drug Deliv       Date:  2015-07-13       Impact factor: 6.648

Review 8.  Systemic side effects of eye drops: a pharmacokinetic perspective.

Authors:  Andre Farkouh; Peter Frigo; Martin Czejka
Journal:  Clin Ophthalmol       Date:  2016-12-07

Review 9.  Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML.

Authors:  Francesca Carofiglio; Antonio Lopalco; Angela Lopedota; Annalisa Cutrignelli; Orazio Nicolotti; Nunzio Denora; Angela Stefanachi; Francesco Leonetti
Journal:  Int J Mol Sci       Date:  2020-06-23       Impact factor: 5.923

Review 10.  Availability of Authorizations from EMA and FDA for Age-Appropriate Medicines Contained in the WHO Essential Medicines List for Children 2019.

Authors:  Jose-Manuel delMoral-Sanchez; Isabel Gonzalez-Alvarez; Marta Gonzalez-Alvarez; Andres Navarro-Ruiz; Marival Bermejo
Journal:  Pharmaceutics       Date:  2020-04-01       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.